contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


carasent-ab-publ-year-end-report-january-december-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Carasent is an IT company. The company delivers products and services within communication and IT infrastructure specifically aimed at the healthcare industry. Examples of solutions include proprietary cloud-based services, email management, mobile solutions, and security and backup solutions. Customers are mainly found within health and care, finance and telecom. The company was originally established in 1997 and is headquartered in Gothenburg.

redeye.se              Carasent (Q3 Review): In good shape for exciting 2026    Redeye retains its positive view of Carasent following the Q3 report. Organic ARR growth remains solid, and margins are improving substantially. The company has several ongoing growth initiatives tha                             Carasents rentabilitetsvending fortsætter på sporet.

Hvilken mægler? Kontakt dem, så skal det nok ordne sig.

Jeg har Carasent ASA for flere tusinde. Det handles ikke længere, så jeg sidder fast med aktierne. Jeg troede, der ville være en automatisk ombytning til Carasent AB… Er der andre i samme situation? Hvad skal jeg gøre? Hvordan forhindrer man dette i fremtiden?

redeye.se              Carasent: Back in Shape in 2024 – More to Come    Redeye retains its positive view of Carasent following the Q4 report. Despite a somewhat softer Q4 report than expected and a softened outlook for H1 2025, we changed our Base Case driven by revised                              Ny basiscase SEK28 (NOK26.5)  Vi hæver vores basiscase til SEK28 (NOK26.5) på grund af en lidt lavere WACC, hævede mellem- og langsigtede marginantagelser og en større tillid til de langsigtede TAM-udsigter i Sverige. Handlet til ca. 3,6x salg 2025e ser Carasent måske ikke så attraktiv ud, taget dets bløde LTM-marginer i betragtning. Dog mener vi, at Carasent er klar til betydelig marginudvidelse i løbet af de næste par år. Med en R40, der nærmer sig 30-35% i 2026-2027, sammen med en meget lav churn og et ikke-cyklisk slutmarked, mener vi, at Carasents værdiansættelse kunne nærme sig R40 SaaS-virksomheder, der typisk værdiansættes til 6-8x salg NTM (eksklusive Fortnox).

access.dnbcarnegie.com              DNB Carnegie Access:                               ja                   redeye.se              Carasent Q4: Slightly Softer than Expected    Redeye comments on Carasent’s Q4 report, showing slightly softer numbers than expected. However, our positive long-term view is unchanged.

Redeye forventninger til regnskabet den 13.2.

Carnegielta har bestilt analyse før Q4                   Inderes              Carnegie Access: Carasent: We expect a solid end to the year – Q4 preview -...    Carnegie has published a new commissioned research report on Carasent.To access the full report and subscribe to future updates, visit https://www.carnegie.se/en/commissioned-research/carasent...

Carasent

Q4 2025 highlightsNet sales amounted to MSEK 93.6 (78.7), corresponding to a net sales growth of 19%.Organic growth amounted to 16%, while net acquisitions and divestments in the last twelve...

<div class="mfn-body"><p><strong>Q4 2025 highlights</strong></p><ul><li>Net sales amounted to MSEK 93.6 (78.7), corresponding to a net sales growth of 19%.</li><li>Organic growth amounted to 16%, while net acquisitions and divestments in the last twelve months accounted for MSEK 3.0 or 4 percentage points of growth.</li><li>EBITDA amounted to MSEK 23.8 (-8.7), corresponding to an EBITDA margin of 25% (-11%).</li><li>Adjusted EBITDA margin was 25% (15%).</li><li>Operating result, EBIT, amounted to MSEK 7.8 (-24.1).</li><li>EBITDAC margin was 16% (-21%)</li><li>Cash flow from operating activities amounted to MSEK 20.6 (16.3).</li><li>Profit after tax amounted to MSEK 29.1 (-24.2).</li><li>Earnings per share, before and after dilution, amounted to SEK 0.42 (-0.34).</li></ul><p><strong>FY 2025 highlights</strong></p><ul><li>Net sales amounted to MSEK 343.8 (275.3), corresponding to a net sales growth of 25%. </li><li>Organic growth amounted to 14%, while net acquisitions and divestments in the last twelve months accounted for MSEK 31.1 or 11 percentage points of growth.</li><li>EBITDA amounted to MSEK 73.3 (11.6), corresponding to an EBITDA margin of 21% (4%). </li><li>Adjusted EBITDA margin was 21% (15%). </li><li>Operating result, EBIT amounted to MSEK 9.4 (-54.5). </li><li>EBITDAC margin was 10% (-11%)</li><li>Cash flow from operating activities amounted to MSEK 40.4 (37.7). </li><li>Profit after tax amounted to MSEK 34.8 (-42.3).</li><li>Earnings per share, before and after dilution, amounted to SEK 0.5 (-0.59).</li></ul><p>The results will be presented as a webcast at 8:00 CET today. If you wish to participate via webcast please use the link below.<br><a rel="noopener" href="https://events.inderes.com/carasent/q4-report-2025">https://events.inderes.com/carasent/q4-report-2025</a><br><br>For further details please contact:<br>Daniel Öhman, CEO Tel: +46 70-855 37 07, or<br>Svein Martin Bjørnstad, CFO Tel: +47 979 69 493</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that Carasent is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-12 07:00 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/94d49000-6655-4ec1-a5dd-f02adac31049/carasent-q42025-en.pdf" class="mfn-primary">Carasent Q42025 En</a><br><a rel="noopener" href="https://storage.mfn.se/e4ed78a0-524f-4675-aaaa-34e378ab5b25/carasent-q4-2025-presentation.pdf">Carasent Q4 2025 Presentation</a></p></div>